Table 3.
Effect | Hazard ratio | 95% hazard ratio confidence limits | P-value | |
---|---|---|---|---|
QOL (vs. > 50)1 | ||||
Deficit (QOL ≤ 50) | 1.841 | 1.440 | 2.354 | <0.0001 |
Age, years (vs. ≥ 80)1 | ||||
<60 | 0.395 | 0.278 | 0.562 | <0.0001 |
60–69.999 | 0.489 | 0.351 | 0.680 | <0.0001 |
70–79.999 | 0.795 | 0.582 | 1.085 | 0.1479 |
Sex (vs. male)1 | ||||
Female | 0.782 | 0.639 | 0.957 | 0.0169 |
ECOG performance status (vs. 2, 3, 4)1 | ||||
0, 1 | 0.448 | 0.344 | 0.585 | <0.0001 |
Smoking cessation (vs. kept smoking)1 | ||||
Quit | 0.496 | 0.336 | 0.733 | 0.0004 |
Tumor size (>2 cm)1 | ||||
≤2 cm | 0.702 | 0.563 | 0.874 | 0.0016 |
Regional nodal involvement (vs. metastasis in contralateral mediastinal)1 | ||||
No nodal metastases | 0.259 | 0.156 | 0.428 | <0.0001 |
In ipsilateral peribronchial and/or ipsilateral hilar nodes | 0.402 | 0.231 | 0.701 | 0.0013 |
In ipsilateral mediastinal and/or subcarinal nodes | 0.574 | 0.345 | 0.954 | 0.0323 |
Distant metastasis (vs. presence)1 | ||||
Absence | 0.274 | 0.204 | 0.368 | <0.0001 |
QOL, quality of life; ECOG, Eastern Cooperative Oncology Group.
Reference group.